{"id":"https://openalex.org/W652920478","doi":"https://doi.org/10.1212/wnl.84.14_supplement.p4.032","title":"Optimizing the Natalizumab Dose Interval to Reduce PML Risk- Lessons from the Pharmacokinetics of Therapy Discontinuation (P4.032)","display_name":"Optimizing the Natalizumab Dose Interval to Reduce PML Risk- Lessons from the Pharmacokinetics of Therapy Discontinuation (P4.032)","publication_year":2015,"publication_date":"2015-04-06","ids":{"openalex":"https://openalex.org/W652920478","doi":"https://doi.org/10.1212/wnl.84.14_supplement.p4.032","mag":"652920478"},"language":"en","primary_location":{"id":"doi:10.1212/wnl.84.14_supplement.p4.032","doi":"https://doi.org/10.1212/wnl.84.14_supplement.p4.032","is_oa":false,"landing_page_url":"https://doi.org/10.1212/wnl.84.14_supplement.p4.032","pdf_url":null,"source":{"id":"https://openalex.org/S79704628","display_name":"Neurology","issn_l":"0028-3878","issn":["0028-3878","1526-632X"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Neurology","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5027116773","display_name":"John F. Foley","orcid":"https://orcid.org/0000-0003-0431-7067","observed_orcids":["https://orcid.org/0000-0003-0431-7067"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"John Foley","raw_affiliation_strings":["Salt Lake City UT United States","1Salt Lake City UT United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Salt Lake City UT United States","institution_ids":[]},{"raw_affiliation_string":"1Salt Lake City UT United States","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5012380785","display_name":"Ryan R. Metzger","orcid":"https://orcid.org/0000-0003-0906-7108","observed_orcids":["https://orcid.org/0000-0003-0906-7108"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Ryan Metzger","raw_affiliation_strings":["Rocky Mountain MS Research Group Salt Lake City UT United States","2Rocky Mountain MS Research Group Salt Lake City UT United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Rocky Mountain MS Research Group Salt Lake City UT United States","institution_ids":[]},{"raw_affiliation_string":"2Rocky Mountain MS Research Group Salt Lake City UT United States","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5033188337","display_name":"Tamara Hoyt","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Tamara Hoyt","raw_affiliation_strings":["Rocky Mountain MS Research Group Salt Lake City UT United States","2Rocky Mountain MS Research Group Salt Lake City UT United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Rocky Mountain MS Research Group Salt Lake City UT United States","institution_ids":[]},{"raw_affiliation_string":"2Rocky Mountain MS Research Group Salt Lake City UT United States","institution_ids":[]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5024583397","display_name":"Angelene Christensen","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Angelene Christensen","raw_affiliation_strings":["Rocky Mountain MS Research Group Salt Lake City UT United States","2Rocky Mountain MS Research Group Salt Lake City UT United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Rocky Mountain MS Research Group Salt Lake City UT United States","institution_ids":[]},{"raw_affiliation_string":"2Rocky Mountain MS Research Group Salt Lake City UT United States","institution_ids":[]}]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":0.1457,"has_fulltext":false,"cited_by_count":1,"citation_normalized_percentile":{"value":0.54463262,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":89,"max":94},"biblio":{"volume":"84","issue":"14_supplement","first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11827","display_name":"Polyomavirus and related diseases","score":0.7099999785423279,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11827","display_name":"Polyomavirus and related diseases","score":0.7099999785423279,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10137","display_name":"Multiple Sclerosis Research Studies","score":0.1185000017285347,"subfield":{"id":"https://openalex.org/subfields/2734","display_name":"Pathology and Forensic Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11016","display_name":"Monoclonal and Polyclonal Antibodies Research","score":0.014299999922513962,"subfield":{"id":"https://openalex.org/subfields/2741","display_name":"Radiology, Nuclear Medicine and Imaging"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/natalizumab","display_name":"natalizumab","score":0.9110000133514404},{"id":"https://openalex.org/keywords/progressive-multifocal-leukoencephalopathy","display_name":"progressive multifocal leukoencephalopathy","score":0.9810000061988831},{"id":"https://openalex.org/keywords/pharmacokinetics","display_name":"pharmacokinetics","score":0.8259999752044678},{"id":"https://openalex.org/keywords/serum-drug-levels","display_name":"serum drug concentration","score":0.6370000243186951},{"id":"https://openalex.org/keywords/drug-clearance","display_name":"drug clearance","score":0.5199999809265137},{"id":"https://openalex.org/keywords/body-weight","display_name":"body weight","score":0.7979999780654907},{"id":"https://openalex.org/keywords/dimethyl-fumarate","display_name":"dimethyl fumarate","score":0.7540000081062317},{"id":"https://openalex.org/keywords/multiple-sclerosis","display_name":"multiple sclerosis","score":0.6449999809265137},{"id":"https://openalex.org/keywords/treatment-discontinuation","display_name":"treatment discontinuation","score":0.7450000047683716},{"id":"https://openalex.org/keywords/crossover-design","display_name":"crossover design","score":0.6330000162124634},{"id":"https://openalex.org/keywords/steady-state-dosing","display_name":"steady-state dosing","score":0.6340000033378601},{"id":"https://openalex.org/keywords/pharmacovigilance","display_name":"pharmacovigilance","score":0.5440000295639038}],"concepts":[{"id":"https://openalex.org/C2778715236","wikidata":"https://www.wikidata.org/wiki/Q55622662","display_name":"Discontinuation","level":2,"score":0.9142807722091675},{"id":"https://openalex.org/C2781004633","wikidata":"https://www.wikidata.org/wiki/Q386119","display_name":"Natalizumab","level":3,"score":0.850979208946228},{"id":"https://openalex.org/C112705442","wikidata":"https://www.wikidata.org/wiki/Q323936","display_name":"Pharmacokinetics","level":2,"score":0.7579522132873535},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.7532729506492615},{"id":"https://openalex.org/C110446960","wikidata":"https://www.wikidata.org/wiki/Q762316","display_name":"Foley","level":2,"score":0.7436084151268005},{"id":"https://openalex.org/C44249647","wikidata":"https://www.wikidata.org/wiki/Q208498","display_name":"Confidence interval","level":2,"score":0.49130740761756897},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.3337472677230835},{"id":"https://openalex.org/C141071460","wikidata":"https://www.wikidata.org/wiki/Q40821","display_name":"Surgery","level":1,"score":0.17450740933418274},{"id":"https://openalex.org/C2779134260","wikidata":"https://www.wikidata.org/wiki/Q12136","display_name":"Disease","level":2,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1212/wnl.84.14_supplement.p4.032","doi":"https://doi.org/10.1212/wnl.84.14_supplement.p4.032","is_oa":false,"landing_page_url":"https://doi.org/10.1212/wnl.84.14_supplement.p4.032","pdf_url":null,"source":{"id":"https://openalex.org/S79704628","display_name":"Neurology","issn_l":"0028-3878","issn":["0028-3878","1526-632X"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Neurology","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":1.0}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W1436613654","https://openalex.org/W120548096","https://openalex.org/W2923273291","https://openalex.org/W3087476458","https://openalex.org/W3203817900","https://openalex.org/W2338026072","https://openalex.org/W4403320599","https://openalex.org/W4230331568","https://openalex.org/W2573401785","https://openalex.org/W2613546953"],"abstract_inverted_index":{"OBJECTIVE:":[0],"To":[1],"utilize":[2],"the":[3,29,52,144,217,239],"pharmacokinetic":[4],"decay":[5],"curve":[6],"after":[7],"natalizumab":[8,24,48,62,72,102,152,226,273],"discontinuation":[9],"for":[10,55,251],"defining":[11],"maximal":[12],"dose":[13,56,213,227,265],"extension.":[14],"BACKGROUND:":[15],"Previous":[16],"findings":[17],"suggest":[18],"a":[19,42,77,129,161,210,229,264,290],"possible":[20],"protective":[21],"effect":[22,255],"of":[23,31,76,131,146,163,178,219,231,236,241,248,256],"dosing":[25,287],"interval":[26,54],"extension":[27,57],"on":[28],"risk":[30,283],"developing":[32],"Progressive":[33],"Multifocal":[34],"Leukoencephalopathy":[35],"(PML).":[36],"Prior":[37],"studies":[38],"have":[39,228],"also":[40,150],"identified":[41],"relationship":[43],"between":[44],"patient":[45],"weight":[46,149,270],"and":[47,98,101,111,275],"serum":[49,103],"concentration.":[50],"However,":[51],"optimal":[53,252],"remains":[58,259],"undefined.":[59],"DESIGN/METHODS:":[60],"27":[61],"patients":[63,157,170,194,220],"(dosed":[64],"at":[65,88,221],"5-6":[66,211],"week":[67,123,212],"intervals)":[68],"were":[69,86,105,109,191],"discontinued":[70],"from":[71,128,209],"therapy":[73],"as":[74],"part":[75],"pilot":[78],"crossover":[79],"study":[80],"to":[81,92,113,121,134,142,165,181,280],"dimethyl":[82],"fumarate.":[83],"Serum":[84],"samples":[85],"obtained":[87],"baseline":[89],"(just":[90],"prior":[91],"last":[93,225],"infusion),":[94],"4,":[95],"8,":[96],"12":[97],"16":[99],"weeks,":[100],"concentrations":[104,124,190],"assessed.":[106],"Patient":[107,148],"weights":[108],"recorded":[110],"stratified":[112],"<=70":[114],"kg":[115,156,173,196,199],"or":[116],">70":[117,155,198],"kg.":[118],"RESULTS:":[119],"Baseline":[120],"8":[122,222],"declined":[125,174],"by":[126],"69[percnt]":[127],"mean":[130,162,177,189],"20.2":[132],"ug/mL":[133,136,180],"6.6":[135],"(p<0.001),":[137],"with":[138,154,234,268,285],"9/27":[139],"(33[percnt])":[140],"declining":[141,158],"below":[143,238],"limit":[145,240,247],"quantification.":[147,242],"influenced":[151],"concentrations,":[153],"79[percnt]":[159],"(from":[160,176],"12.1":[164],"2.5":[166],"ug/mL;":[167,183],"p=0.001)":[168],"whereas":[169],"<=":[171],"70":[172],"61[percnt]":[175],"33.9":[179],"13.3":[182],"p=0.004).":[184],"Across":[185],"all":[186],"data":[187],"points,":[188],"higher":[192,272],"in":[193,263,289],"<70":[195],"vs":[197,201],"(19.4ug/mL":[200],"7.5":[202],"ug/mL,":[203],"respectively;":[204],"p<0.001).":[205],"CONCLUSIONS:":[206],"When":[207],"starting":[208],"extended":[214,266,286],"steady":[215],"state,":[216],"majority":[218],"weeks":[223],"post":[224],"concentration":[230,274],"<":[232],"10ug/mL":[233],"33[percnt]":[235],"these":[237],"This":[243],"suggests":[244],"an":[245],"upper":[246],"6-week":[249],"intervals":[250,288],"efficacy.":[253],"The":[254],"body":[257],"mass":[258],"quite":[260],"pronounced":[261],"even":[262],"population,":[267],"lower":[269],"portending":[271],"reduced":[276],"clearance.":[277],"Concurrent":[278],"analysis":[279],"define":[281],"PML":[282],"reduction":[284],"multicenter":[291],"trial":[292],"is":[293],"ongoing.":[294],"Study":[295],"Supported":[296],"by:":[297],"Biogen":[298],"Idec":[299]},"counts_by_year":[{"year":2017,"cited_by_count":1}],"updated_date":"2026-09-22T06:50:58.402377","created_date":"2016-06-24T00:00:00"}